Perspective and potential of oral lipid-based delivery to optimize pharmacological therapies against cardiovascular diseases

Journal of Controlled Release

Volumn 193, Issue , 2014, Pages 174-187

  Rao, Shasha ^a   Tan, Angel ^a   Thomas, Nicky ^a   Prestidge, Clive A ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Cardiovascular disease; Combined therapy; Controlled drug release; Lipid based drug delivery; Oral bioavailability; Targeted delivery

Indexed keywords

BIOCHEMISTRY; CARDIOLOGY; CLINICAL RESEARCH; CONTROLLED DRUG DELIVERY; DISEASE CONTROL; DISEASES;

CARDIO-VASCULAR DISEASE; COMBINED THERAPY; CONTROLLED DRUG RELEASE; ORAL BIOAVAILABILITIES; TARGETED DELIVERY;

TARGETED DRUG DELIVERY;

CARDIOVASCULAR AGENT; DRUG CARRIER; NANOSTRUCTURED LIPID CARRIER; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; EMULSION; LIPID; NANOPARTICLE; SOLUTION AND SOLUBILITY; SUSPENSION;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; LIPID BASED DRUG DELIVERY SYSTEM; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; PARTICLE SIZE; REVIEW; SOLUBILIZATION; BIOAVAILABILITY; CARDIOVASCULAR DISEASES; CHEMISTRY; DELAYED RELEASE FORMULATION; EMULSION; FOOD DRUG INTERACTION; METABOLISM; ORAL DRUG ADMINISTRATION; SOLUTION AND SOLUBILITY; SUSPENSION; TRENDS;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; FOOD-DRUG INTERACTIONS; HUMANS; LIPIDS; NANOPARTICLES; SOLUTIONS; SUSPENSIONS;

EID: 84908267530     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.05.013     Document Type: Review

References (163)

1. World Heart Federation Different heart diseases http://www.world-heart-federation.org/cardiovascular-health/heart-disease/different-heart-diseases/ (accessed 01/05/2014)
2. A. Alwan Global Status Report on Noncommunicable Diseases 2010 2011 World Health Organization Press Geneva
3. K.K. Jain Applications of Biotechnology in Cardiovascular Therapeutics 2011 Humana Press Basel, Switzerland
4. Cardiovascular drugs/cardiology drugs FDA Approved Drugs vol. 2014 2014
5. E. Palmer, and C. Helfand Top 10 cardio drugs 2012 http://www.fiercepharma.com/special-reports/top-10-cardio-drugs-2012 (accessed 01/05/2014)
6. B. Katz, A. Rosenberg, and W.H. Frishman Controlled-release drug delivery systems in cardiovascular medicine Am. Heart J. 129 2 1995 359 368
7. D.G. Fatouros, D.M. Karpf, F.S. Nielsen, and A. Mullertz Clinical studies with oral lipid based formulations of poorly soluble compounds Ther. Clin. Risk Manag. 3 4 2007 591 604
8. A. Tan, A. Martin, T.-H. Nguyen, B.J. Boyd, and C.A. Prestidge Hybrid nanomaterials that mimic the food effect: controlling enzymatic digestion for enhanced oral drug absorption Angew. Chem. Int. Ed. 124 22 2012 5571 5575
9. D.J. Hauss, S.E. Fogal, J.V. Ficorilli, C.A. Price, T. Roy, A.A. Jayaraj, and J.J. Keirns Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor J. Pharm. Sci. 87 2 1998 164 169
10. S.-M. Khoo, D.M. Shackleford, C.J.H. Porter, G.A. Edwards, and W.N. Charman Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs Pharm. Res. 20 9 2003 1460 1465
11. P.P. Constantinides, and K.M. Wasan Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies J. Pharm. Sci. 96 2 2007 235 248
12. X. Dong, C.A. Mattingly, M.T. Tseng, M.J. Cho, Y. Liu, V.R. Adams, and R.J. Mumper Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP Cancer Res. 69 9 2009 3918 3926
13. C.J.H. Porter, N.L. Trevaskis, and W.N. Charman Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discov. 6 2007 231 248
14. H.-Y. Yun, E. Lee, S. Chung, S.-O. Choi, H. Kim, J.-T. Kwon, W. Kang, and K.-I. Kwon The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule Clin. Pharmacokinet. 45 4 2006 425 432
15. Y. Park, H.-K. Lee, Y. Im, W. Lee, and H.-K. Han Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion Arch. Pharm. Res. 33 8 2010 1235 1240
16. T. Julianto, K.H. Yuen, and A.M. Noor Improved bioavailability of vitamin E with a self emulsifying formulation Int. J. Pharm. 200 1 2000 53 57
17. A. Rasool, A.R. Rahman, K. Yuen, and A. Wong Arterial compliance and vitamin E blood levels with a self emulsifying preparation of tocotrienol rich vitamin E Arch. Pharm. Res. 31 9 2008 1212 1217
18. L. Wei, P. Sun, S. Nie, and W. Pan Preparation and evaluation of SEDDS and SMEDDS containing carvedilol Drug Dev. Ind. Pharm. 31 8 2005 785 794
19. B. Lee, M. Kang, W. Choi, Y. Choi, H. Kim, S. Lee, J. Lee, and Y. Choi Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability Arch. Pharm. Res. 32 11 2009 1629 1635
20. M.J. Kang, H.S. Kim, H.S. Jeon, J.H. Park, B.S. Lee, B.K. Ahn, K.Y. Moon, and Y.W. Choi In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system Drug Dev. Ind. Pharm. 38 5 2012 587 596
21. F. Guo, H. Zhong, J. He, B. Xie, F. Liu, H. Xu, M. Liu, and C. Xu Self-microemulsifying drug delivery system for improved oral bioavailability of dipyridamole: preparation and evaluation Arch. Pharm. Res. 34 7 2011 1113 1123
22. K. Balakumar, C.V. Raghavan, N.T. Selvan, R.H. Prasad, and S. Abdu Self nanoemulsifying drug delivery system (SNEDDS) of rosuvastatin calcium: design, formulation, bioavailability and pharmacokinetic evaluation Colloids Surf. B: Biointerfaces 112 2013 337 343
23. J. Patel, G. Kevin, A. Patel, M. Raval, and N. Sheth Design and development of a self-nanoemulsifying drug delivery system for telmisartan for oral drug delivery Int. J. Pharm. Invest. 1 2 2011 112 118
24. J. Ahmad, K. Kohli, S.R. Mir, and S. Amin Formulation of self-nanoemulsifying drug delivery system for telmisartan with improved dissolution and oral bioavailability J. Dispers. Sci. Technol. 32 7 2011 958 968
25. D. Ghai, and V.R. Sinha Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of the poorly water-soluble selective β1-adrenoreceptor blocker talinolol Nanomedicine 8 5 2012 618 626
26. P. Balakrishnan, B.-J. Lee, D.H. Oh, J.O. Kim, Y.-I. Lee, D.-D. Kim, J.-P. Jee, Y.-B. Lee, J.S. Woo, C.S. Yong, and H.-G. Choi Enhanced oral bioavailability of coenzyme Q10 by self-emulsifying drug delivery systems Int. J. Pharm. 374 1-2 2009 66 72
27. Y. Kawabata, K. Wada, M. Nakatani, S. Yamada, and S. Onoue Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications Int. J. Pharm. 420 1 2011 1 10
28. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 1 2000 47 60
29. F. Vanderbist, A. Sereno, P. Baudier, Oral Pharmaceutical Composition Containing A Statin Derivative, United States Patent US 2004/0235935, 2004.
30. C.W. Pouton Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems Eur. J. Pharm. Biopharm. 11 Supplement 2 2000 S93 S98
31. C. Solans, P. Izquierdo, J. Nolla, N. Azemar, and M.J. Garcia-Celma Nano-emulsions Curr. Opin. Colloid Interface Sci. 10 3-4 2005 102 110
32. D.J. McClements, and Y. Li Structured emulsion-based delivery systems: controlling the digestion and release of lipophilic food components Adv. Colloid Interface Sci. 159 2 2010 213 228
33. F. Gao, Z. Zhang, H. Bu, Y. Huang, Z. Gao, J. Shen, C. Zhao, and Y. Li Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism J. Control. Release 149 2 2011 168 174
34. D.J. McClements Nanoemulsions versus microemulsions: terminology, differences, and similarities Soft Matter 8 6 2012 1719 1729
35. Y. Gong, Y. Wu, C. Zheng, L. Fan, F. Xiong, and J. Zhu An excellent delivery system for improving the oral bioavailability of natural vitamin E in rats AAPS PharmSciTech 13 3 2012 961 966
36. M.Y. Levy, W. Schutze, C. Fuhrer, and S. Benita Characterization of diazepam submicron emulsion interface: role of oleic acid J. Microencapsul. 11 1 1994 79 92
37. A. Müllertz, A. Ogbonna, S. Ren, and T. Rades New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs J. Pharm. Pharmacol. 62 11 2010 1622 1636
38. A.A. Date, N. Desai, R. Dixit, and M. Nagarsenker Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances Nanomedicine 5 10 2010 1595 1616
39. R. Liu, Q. Pan, P. Hansrani, Novel Formulations Comprising Lipid-Regulating Agents, United States Patent WO/2000/057918, 2000.
40. J. Patel, P.Y. Sanzgiri, D.J. Lipari, M.T. Reiland, L. Novel, Formulations Comprising Lipid-Regulating Agents, United States Patent WO/2000/057859, 2000.
41. N.H. Shah, M.T. Carvajal, C.I. Patel, M.H. Infeld, and A.W. Malick Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs Int. J. Pharm. 106 1 1994 15 23
42. B.K. Kang, J.S. Lee, S.K. Chon, S.Y. Jeong, S.H. Yuk, G. Khang, H.B. Lee, and S.H. Cho Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs Int. J. Pharm. 274 1-2 2004 65 73
43. H. Shen, and M. Zhong Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin J. Pharm. Pharmacol. 58 9 2006 1183 1191
44. G. Mustafa, Z.I. Khan, T. Bansal, and S. Talegaonkar Preparation and characterization of oil in water nano-reservoir systems for improved oral delivery of atorvastatin Curr. Nanosci. 5 4 2009 428 440
45. N. Thomas, R. Holm, A. Müllertz, and T. Rades In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS) J. Control. Release 160 1 2012 25 32
46. E.A. Mueller, J.M. Kovarik, J.B. van Bree, J. Grevel, P.W. Lücker, and K. Kutz Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation Pharm. Res. 11 1 1994 151 155
47. A.K. Trull, K.K. Tan, L. Tan, G.J. Alexander, and N.V. Jamieson Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion Br. J. Clin. Pharmacol. 39 6 1995 627 631
48. A. Lippacher, R.H. Müller, and K. Mäder Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles Int. J. Pharm. 214 1-2 2001 9 12
49. A. Lippacher, R.H. Müller, and K. Mäder Liquid and semisolid SLN(TM) dispersions for topical application: rheological characterization Eur. J. Pharm. Biopharm. 58 3 2004 561 567
50. S. Nazzal, I.I. Smalyukh, O.D. Lavrentovich, and M.A. Khan Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formation Int. J. Pharm. 235 1-2 2002 247 265
51. W. Phuapradit, N.H. Shah, Y. Lou, S. Kundu, and M.H. Infeld Critical processing factors affecting rheological behavior of a wax based formulation Eur. J. Pharm. Biopharm. 53 2 2002 175 179
52. N.H. Shah, W. Phuapradit, Y.-E. Zhang, H. Ahmed, and A.W. Malick D.J. Hauss, Oral Lipid-Based Formulations 2007 Informa Healthcare USA, Inc. New York 129 148
53. E.T. Cole, D. Cadé, and H. Benameur Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration Adv. Drug Deliv. Rev. 60 6 2008 747 756
54. M.C. Breitkreitz, G.P. Sabin, G. Polla, and R.J. Poppi Characterization of semi-solid self-emulsifying drug delivery systems (SEDDS) of atorvastatin calcium by Raman image spectroscopy and chemometrics J. Pharm. Biomed. Anal. 73 25 2013 3 12
55. N.A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernäs, A.S. Hussain, H.E. Junginger, S.A. Stavchansky, K.K. Midha, V.P. Shah, and G.L. Amidon Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol. Pharm. 1 1 2003 85 96
56. B.J. Boyd, S.-M. Khoo, D.V. Whittaker, G. Davey, and C.J.H. Porter A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats Int. J. Pharm. 340 1-2 2007 52 60
57. K.W.Y. Lee, T.-H. Nguyen, T. Hanley, and B.J. Boyd Nanostructure of liquid crystalline matrix determines in vitro sustained release and in vivo oral absorption kinetics for hydrophilic model drugs Int. J. Pharm. 365 2009 190 199
58. J. Lai, J. Chen, Y. Lu, J. Sun, F. Hu, Z. Yin, and W. Wu Glyceryl monooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems: I. In vitro evaluation and enhanced oral bioavailability of the poorly water-soluble drug simvastatin AAPS PharmSciTech 10 3 2009 960 966
59. A. Tan, S. Rao, and C. Prestidge Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance Pharm. Res. 2013 1 25
60. Z. Wang, J. Sun, Y. Wang, X. Liu, Y. Liu, Q. Fu, P. Meng, and Z. He Solid self-emulsifying nitrendipine pellets: preparation and in vitro/in vivo evaluation Int. J. Pharm. 383 1-2 2010 1 6
61. D.-J. Jang, E.J. Jeong, H.-M. Lee, B.-C. Kim, S.-J. Lim, and C.-K. Kim Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion Eur. J. Pharm. Sci. 28 5 2006 405 411
62. S. Beg, S. Swain, H. Singh, C. Patra, and M. Rao Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers AAPS PharmSciTech 13 4 2012 1416 1427
63. S. Rao, A. Tan, B.J. Boyd, and C.A. Prestidge Synergistic role of self-emulsifying lipids and nanostructured porous silica particles in optimizing the oral delivery of lovastatin Nanomedicine 2014 (in press)
64. A. Tan, A. Davey, and C. Prestidge Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib Pharm. Res. 28 9 2011 2273 2287
65. A. Tan, N. Eskandar, S. Rao, and C. Prestidge First in man bioavailability and tolerability studies of a silica-lipid hybrid (lipoceramic) formulation: a Phase I study with ibuprofen Drug Deliv. Transl. Res. 2013 1 10
66. A. Tan, and C. Prestidge Nanostructured silica-lipid hybrid microparticles: a supersaturating carrier for water- and lipid-resistant compounds Chem. Lett. 41 10 2012 1334 1336
67. A. Tan, S. Simovic, A.K. Davey, T. Rades, and C.A. Prestidge Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs J. Control. Release 134 1 2009 62 70
68. K.E. Bremmell, A. Tan, A. Martin, and C.A. Prestidge Tableting lipid-based formulations for oral drug delivery: a case study with silica nanoparticle-lipid-mannitol hybrid microparticles J. Pharm. Sci. 102 2 2013 684 693
69. T.-H. Nguyen, A. Tan, L. Santos, D. Ngo, G.A. Edwards, C.J.H. Porter, C.A. Prestidge, and B.J. Boyd Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: an in vivo evaluation J. Control. Release 167 2013 85 91
70. S. Simovic, T.J. Barnes, A. Tan, and C.A. Prestidge Assembling nanoparticle coatings to improve the drug delivery performance of lipid based colloids Nanoscale 4 4 2012 1220 1230
71. S. Simovic, P. Heard, H. Hui, Y. Song, F. Peddie, A.K. Davey, A. Lewis, T. Rades, and C.A. Prestidge Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs Mol. Pharm. 6 3 2009 861 872
72. R.H. Muller, K. Mader, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 1 2000 161 177
73. G. Suresh, K. Manjunath, V. Venkateswarlu, and V. Satyanarayana Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles AAPS PharmSciTech 8 1 2007 E162 E170
74. C.-C. Chen, T.-H. Tsai, Z.-R. Huang, and J.-Y. Fang Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics Eur. J. Pharm. Biopharm. 74 3 2010 474 482
75. R. Tiwari, and K. Pathak Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake Int. J. Pharm. 415 1-2 2011 232 243
76. J. Dressman, K. Thelen, and E. Jantratid Towards quantitative prediction of oral drug absorption Clin. Pharmacokinet. 47 10 2008 655 667
77. R. Neslihan Gursoy, and S. Benita Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs Biomed. Pharmacother. 58 3 2004 173 182
78. P. Constantinides Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects Pharm. Res. 12 11 1995 1561 1572
79. B. Abuasal, C. Lucas, B. Peyton, A. Alayoubi, S. Nazzal, P. Sylvester, and A. Kaddoumi Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases γ-tocotrienol oral bioavailability Lipids 47 5 2012 461 469
80. K. Thelen, and J.B. Dressman Cytochrome P450-mediated metabolism in the human gut wall J. Pharm. Pharmacol. 61 5 2009 541 558
81. L.Z. Benet, C.-Y. Wu, M.F. Hebert, and V.J. Wacher Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery J. Control. Release 39 2-3 1996 139 143
82. S. Katragadda, B. Budda, B.S. Anand, and A.K. Mitra Role of efflux pumps and metabolising enzymes in drug delivery Expert Opin. Drug Deliv. 2 4 2005 683 705
83. Z. Ge, X.-X. Zhang, L. Gan, and Y. Gan Redispersible, dry emulsion of lovastatin protects against intestinal metabolism and improves bioavailability Acta Pharmacol. Sin. 29 8 2008 990 997
84. A. Shayeganpour, D.A. Hamdy, and D.R. Brocks Effects of intestinal constituents and lipids on intestinal formation and pharmacokinetics of desethylamiodarone formed from amiodarone J. Pharm. Pharmacol. 60 12 2008 1625 1632
85. A. Christiansen, T. Backensfeld, K. Denner, and W. Weitschies Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro Eur. J. Pharm. Biopharm. 78 1 2011 166 172
86. C.J.H. Porter, K.M. Wasan, and P. Constantinides Lipid-based systems for the enhanced delivery of poorly water soluble drugs Adv. Drug Deliv. Rev. 60 2008 615 616
87. S.W. Wang, J. Monagle, C. McNulty, D. Putnam, and H. Chen Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process J. Pharm. Sci. 93 11 2004 2755 2767
88. K. Sachs-Barrable, A. Thamboo, and S.D.L.K.M. Wasan Lipid excipients peceol and gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within caco-2 cells J. Pharm. Pharm. Sci. 10 3 2007 319 331
89. A.B. Thomson, C. Schoeller, M. Keelan, L. Smith, and M.T. Clandinin Lipid absorption: passing through the unstirred layers, brush-border membrane, and beyond Can. J. Physiol. Pharmacol. 71 8 1993 531 555
90. K. Katneni, S.A. Charman, and C.J.H. Porter Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach J. Pharm. Sci. 96 2 2007 280 293
91. E.-M. Collnot, C. Baldes, M.F. Wempe, R. Kappl, J. Hüttermann, J.A. Hyatt, K.J. Edgar, U.F. Schaefer, and C.-M. Lehr Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity Mol. Pharm. 4 3 2007 465 474
92. G. Cornaire, J. Woodley, P. Hermann, A. Cloarec, C. Arellano, and G. Houin Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo Int. J. Pharm. 278 1 2004 119 131
93. N.L. Trevaskis, W.N. Charman, and C.J.H. Porter Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update Adv. Drug Deliv. Rev. 60 6 2008 702 716
94. W.N.A. Charman, and V.J. Stella Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules Int. J. Pharm. 34 1-2 1986 175 178
95. C.J.H. Porter, and W.N. Charman Intestinal lymphatic drug transport: an update Adv. Drug Deliv. Rev. 50 1-2 2001 61 80
96. W.N.A. Charman, and V.J. Stella Effects of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT Int. J. Pharm. 33 1-3 1986 165 172
97. S.M. Caliph, W.N. Charman, and C.J.H. Porter Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats J. Pharm. Sci. 89 2000 1073 1084
98. K. Manjunath, and V. Venkateswarlu Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration J. Drug Target. 14 9 2006 632 645
99. R.K. Ockner, J.P. Pittman, and J.L. Yager Differences in the intestinal absorption of saturated and unsaturated long chain fatty acids Gastroenterology 62 5 1972 981 992
100. D.M. Sheehe, J.B. Green, and M.H. Green Influence of dietary fat saturation on lipid absorption in the rat Atherosclerosis 37 2 1980 301 310
101. A. Bargoni, R. Cavalli, O. Caputo, A. Fundarò, M. Gasco, and G. Zara Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats Pharm. Res. 15 5 1998 745 750
102. R. Paliwal, S. Rai, B. Vaidya, K. Khatri, A.K. Goyal, N. Mishra, A. Mehta, and S.P. Vyas Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery Nanomedicine 5 2 2009 184 191
103. B. Sanjula, F.M. Shah, A. Javed, and A. Alka Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement J. Drug Target. 17 3 2009 249 256
104. Z. Zhang, F. Gao, H. Bu, J. Xiao, and Y. Li Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats Nanomedicine 8 5 2012 740 747
105. A. Dahan, and A. Hoffman Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs Eur. J. Pharm. Sci. 24 4 2005 381 388
106. V.K. Venishetty, R. Chede, R. Komuravelli, L. Adepu, R. Sistla, and P.V. Diwan Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration Colloids Surf. B: Biointerfaces 95 2012 1 9
107. F. Nacka, M. Cansell, and B. Entressangles In vitro behavior of marine lipid-based liposomes. influence of pH, temperature, bile salts, and phospholipase A2 Lipids 36 1 2001 35 42
108. M. Cansell, F. Nacka, and N. Combe Marine lipid-based liposomes increase in vivo FA bioavailability Lipids 38 5 2003 551 559
109. F. Nacka, M. Cansell, J.P. Gouygou, C. Gerbeaud, P. Méléard, and B. Entressangles Physical and chemical stability of marine lipid-based liposomes under acid conditions Colloids Surf. B: Biointerfaces 20 3 2001 257 266
110. F. Nacka, M. Cansell, P. Méléard, and N. Combe Incorporation of α-tocopherol in marine lipid-based liposomes: in vitro and in vivo studies Lipids 36 12 2001 1313 1320
111. P. Durrington, D. Bhatnagar, M. Mackness, J. Morgan, K. Julier, M. Khan, and M. France An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia Br. Heart J. 85 5 2001 544 548
112. Bønaa Nordøy, Berge Nilsen, and Ingebretsen Hansen Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia J. Intern. Med. 243 2 1998 163 170
113. B.-N. Ahn, S.-K. Kim, and C.-K. Shim Preparation and evaluation of proliposomes containing propranolol hydrochloride J. Microencapsul. 12 4 1995 363 375
114. M.L. Van Slooten, O. Boerman, K. Romøren, E. Kedar, D.J.A. Crommelin, and G. Storm Liposomes as sustained release system for human interferon-γ: biopharmaceutical aspects Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1530 2-3 2001 134 145
115. M.A. Momoh, F.C. Kenechukwu, and A.A. Attama Formulation and evaluation of novel solid lipid microparticles as a sustained release system for the delivery of metformin hydrochloride Drug Deliv. 20 3-4 2013 102 111
116. S.N. Patere, N.S. Desai, A.S. Jain, P.P. Kadam, U.M. Thatte, N. Gogtay, C.J. Kapadia, N. Farah, and M.S. Nagarsenker Compritol(r) 888 ATO a lipid excipient for sustained release of highly water soluble active: formulation, scale-up and IVIVC study Curr. Drug Deliv. 10 5 2013 548 556
117. V.V. Kumar, D. Chandrasekar, S. Ramakrishna, V. Kishan, Y.M. Rao, and P.V. Diwan Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics Int. J. Pharm. 335 1-2 2007 167 175
118. A.J. Almeida, and E. Souto Solid lipid nanoparticles as a drug delivery system for peptides and proteins Adv. Drug Deliv. Rev. 59 6 2007 478 490
119. A.L. Weiner Liposomes for protein delivery: selecting manufacture and development processes ImmunoMethods 4 3 1994 201 209
120. S. Martins, B. Sarmento, D.C. Ferreira, and E.B. Souto Lipid-based colloidal carriers for peptide and protein delivery - liposomes versus lipid nanoparticles Int. J. Nanomedicine 2 4 2007 595 607
121. V. Marinkovic, D. Agbaba, K. Karljikovic-Rajic, J. Comor, and D. Zivanov-Stakic UV derivative spectrophotometric study of the photochemical degradation of nisoldipine Farmaco 55 2 2000 128 133
122. P.A. van Zwieten, and M. Pfaffendorf Similarities and differences between calcium antagonists: pharmacological aspects J. Hypertens. 11 Suppl. 1 1993 S3 S11
123. H.H. Tønnesen, and J. Karlsen Studies on curcumin and curcuminoids. X. The use of curcumin as a formulation aid to protect light-sensitive drugs in soft gelatin capsules Int. J. Pharm. 38 1-3 1987 247 249
124. D.S. Desai, M.A. Abdelnasser, B.A. Rubitski, and S.A. Varia Photostabilization of uncoated tablets of sorivudine and nifedipine by incorporation of synthetic iron oxides Int. J. Pharm. 103 1 1994 69 76
125. A.H.L. Ho, A. Puri, and J.K. Sugden Effect of sweetening agents on the light stability of aqueous solutions of l-ascorbic acid Int. J. Pharm. 107 3 1994 199 203
126. G. Ragno, E. Cione, A. Garofalo, G. Genchi, G. Ioele, A. Risoli, and A. Spagnoletta Design and monitoring of photostability systems for amlodipine dosage forms Int. J. Pharm. 265 1-2 2003 125 132
127. G. Ragno, A. Risoli, G. Ioele, E. Cione, and M. De Luca Photostabilization of 1,4-dihydropyridine antihypertensives by incorporation into beta-cyclodextrin and liposomes J. Nanosci. Nanotechnol. 6 9-1 2006 2979 2985
128. G. Ioele, E. Cione, A. Risoli, G. Genchi, and G. Ragno Accelerated photostability study of tretinoin and isotretinoin in liposome formulations Int. J. Pharm. 293 1-2 2005 251 260
129. C. Puglia, F. Bonina, L. Rizza, P. Blasi, A. Schoubben, R. Perrotta, M.S. Tarico, and E. Damiani Lipid nanoparticles as carrier for octyl-methoxycinnamate: in vitro percutaneous absorption and photostability studies J. Pharm. Sci. 101 1 2012 301 311
130. H. Liedholm, and A. Melander Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation Clin. Pharmacol. Ther. 40 1 1986 29 36
131. D.A. Maka, and L.K. Murphy Drug-nutrient interactions: a review AACN Clin. Issues 11 4 2000 580 589
132. A. Ochiai, S. Itagaki, T. Kurokawa, M. Kobayashi, T. Hirano, and K. Iseki Improvement in intestinal coenzyme Q10 absorption by food intake Yakugaku Zasshi 127 8 2007 1251 1254
133. H. Lennernäs, and G. Fager Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences Clin. Pharmacokinet. 32 5 1997 403 425
134. C.H. Gu, H. Li, J. Levons, K. Lentz, R. Gandhi, K. Raghavan, and R.S. Smith Predicting effect of food on extent of drug absorption based on physicochemical properties Pharm. Res. 24 6 2007 1118 1130
135. K. Lentz Current methods for predicting human food effect AAPS J. 10 2 2008 282 288
136. K.A. Lentz, M. Quitko, D.G. Morgan, J.E. Grace, C. Gleason, and P.H. Marathe Development and validation of a preclinical food effect model J. Pharm. Sci. 96 2 2007 459 472
137. L.E. Schmidt, and K. Dalhoff Food-drug interactions Drugs 62 10 2002 1481 1502
138. C.T. Phan, and P. Tso Intestinal lipid absorption and transport Front. Biosci. 6 2001 d299 d319
139. D. Fleisher, C. Li, Y. Zhou, L.H. Pao, and A. Karim Drug, meal and formulation interactions influencing drug absorption after oral administration. clinical implications Clin. Pharmacokinet. 36 3 1999 233 254
140. C.-Y. Wu, and L.Z. Benet Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res. 22 1 2005 11 23
141. S. Chakraborty, D. Shukla, B. Mishra, and S. Singh Lipid - an emerging platform for oral delivery of drugs with poor bioavailability Eur. J. Pharm. Biopharm. 73 1 2009 1 70
142. M. Kuentz Lipid-based formulations for oral delivery of lipophilic drugs Drug Discov. Today Technol. 9 2 2012 e97 e104
143. Y. Chen, G. Li, J.-G. Huang, R.-H. Wang, H. Liu, and R. Tang Comparison of self-microemulsifying drug delivery systems versus solid dispersion technology used in the improvement of dissolution rate and bioavailability of vincopecetine Acta Pharm. Sin. 44 6 2009 658 666
144. N. Thomas, T. Rades, and A. Müllertz Recent developments in oral lipid-based drug delivery J. Drug Deliv. Sci. Technol. 23 4 2013 375 382
145. Z.X. Liu, and C. Artmann Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system Altern. Ther. Health Med. 15 2 2009 42 46
146. B. Abdulwahab, S. Ranjita, D. Michael, and H.M. Rainer Coenzyme Q10 oral bioavailability: effect of formulation type J. Pharm. Invest. 43 2013 431 451
147. D.P. Faxon, T.E. Spiro, S. Minor, G. Coté, J. Douglas, R. Gottlieb, R. Califf, K. Dorosti, E. Topol, J.B. Gordon, and M. Ohmen Low molecular weight heparin in prevention of restenosis after angioplasty: results of enoxaparin restenosis (ERA) trial Circulation 90 2 1994 908 914
148. V. Labhasetwar, C. Song, and R.J. Levy Nanoparticle drug delivery system for restenosis Adv. Drug Deliv. Rev. 24 1 1997 63 85
149. A.M. Lincoff, E.J. Topol, and S.G. Ellis Local drug delivery for the prevention of restenosis: fact, fancy, and future Circulation 90 4 I 1994 2070 2084
150. B. Mishra, B.B. Patel, and S. Tiwari Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery Nanomedicine 6 1 2010 9 24
151. L. Jabr-Milane, L. van Vlerken, H. Devalapally, D. Shenoy, S. Komareddy, M. Bhavsar, and M. Amiji Multi-functional nanocarriers for targeted delivery of drugs and genes J. Control. Release 130 2 2008 121 128
152. I.M. Dauber, K.M. VanBenthuysen, I.F. McMurtry, G.S. Wheeler, E.J. Lesnefsky, L.D. Horwitz, and J.V. Weil Functional coronary microvascular injury evident as increased permeability due to brief ischemia and reperfusion Circ. Res. 66 4 1990 986 998
153. H. Takahama, H. Shigematsu, T. Asai, T. Matsuzaki, S. Sanada, H. Fu, K. Okuda, M. Yamato, H. Asanuma, Y. Asano, M. Asakura, N. Oku, I. Komuro, M. Kitakaze, and T. Minamino Liposomal amiodarone augments anti-arrhythmic effects and reduces hemodynamic adverse effects in an ischemia/reperfusion rat model Cardiovasc. Drugs Ther. 27 2 2013 125 132
154. B.J. Lestini, S.M. Sagnella, Z. Xu, M.S. Shive, N.J. Richter, J. Jayaseharan, A.J. Case, K. Kottke-Marchant, J.M. Anderson, and R.E. Marchant Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery J. Control. Release 78 1-3 2002 235 247
155. G. Fricker, T. Kromp, A. Wendel, A. Blume, J. Zirkel, H. Rebmann, C. Setzer, R.-O. Quinkert, F. Martin, and C. Müller-Goymann Phospholipids and lipid-based formulations in oral drug delivery Pharm. Res. 27 8 2010 1469 1486
156. Working Group on the Summit on Combination Therapy for CVD Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges Eur. Heart J. 35 6 2013 353 364
157. P. Carminati, A.P. Duena, Pharmaceutical Composition Comprising Microcapsules of Statins Suspended in Alkyl Esters of Polyunsaturated Fatty Acids (PUFA), United States Patent, Aug 6, 2009.
158. H. Guzman, J. Remenar, O. Almarsson, Statin Pharmaceutical Compositions and Related Methods of Treatment, United States Patent US 7,642,287, 2010.
159. V. Nambi, and C.M. Ballantyne Combination therapy with statins and omega-3 fatty acids Am. J. Cardiol. 98 4, Supplement 1 2006 34 38
160. D.C. Chan, G.F. Watts, T.A. Mori, P.H.R. Barrett, L.J. Beilin, and T.G. Redgrave Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity Eur. J. Clin. Invest. 32 6 2002 429 436
161. R.P. Dixit, and M.S. Nagarsenker Formulation and in vivo evaluation of self-nanoemulsifying granules for oral delivery of a combination of ezetimibe and simvastatin Drug Dev. Ind. Pharm. 34 12 2008 1285 1296
162. J.A. Hanson, C.B. Chang, S.M. Graves, Z. Li, T.G. Mason, and T.J. Deming Nanoscale double emulsions stabilized by single-component block copolypeptides Nature 455 7209 2008 85 88
163. S.-H. Hu, S.-Y. Chen, and X. Gao Multifunctional nanocapsules for simultaneous encapsulation of hydrophilic and hydrophobic compounds and on-demand release ACS Nano 6 3 2012 2558 2565